- ISIN
- US00654J1079
- CUSIP
- 00654J107
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 29, 2020
Highlights
- Market Cap
- $7.73M
- Enterprise Value
- $5.76M
- EPS (TTM)
- -CHF 6.97
- Total Revenue (TTM)
- CHF 81.81K
- Gross Profit (TTM)
- -CHF 154.75K
- EBITDA (TTM)
- -CHF 5.65M
- Year Range
- $5.41 - $12.05
- Target Price
- $30.00
- ROA (TTM)
- -105.48%
- ROE (TTM)
- -140.87%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ADXN Performance Chart
Addex Therapeutics Ltd (ADXN) is down 15.5% since the beginning of the year. At $7 per share, ADXN is trading 45.9% below its 52-week high of $12. Investors who bought $1,000 worth of ADXN shares 5 years ago would now be looking at an investment worth $32.
Loading charts...
Returns By Period
Addex Therapeutics Ltd (ADXN) has returned -15.54% so far this year and -22.93% over the past 12 months.
Addex Therapeutics Ltd
- 1D
- 5.16%
- 1M
- -4.54%
- YTD
- -15.54%
- 6M
- -22.75%
- 1Y
- -22.93%
- 3Y*
- -20.55%
- 5Y*
- -49.62%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ADXN Monthly Returns History
Based on dividend-adjusted daily data since Jan 29, 2020, ADXN's average daily return is +0.03%, while the average monthly return is -1.83%.
Historically, 33% of months were positive and 67% were negative. The best month was Feb 2023 with a return of +91.6%, while the worst month was Jun 2022 at -69.5%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 8 months.
On a daily basis, ADXN closed higher 41% of trading days. The best single day was Jul 21, 2022 with a return of +110.4%, while the worst single day was Jun 17, 2022 at -55.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.78% | -4.96% | -13.60% | 10.65% | -4.45% | -1.95% | -15.54% | ||||||
| 2025 | 10.00% | 10.39% | -13.65% | 6.16% | 2.92% | 17.33% | -12.86% | -3.66% | 19.68% | -3.65% | -15.87% | 0.72% | 10.29% |
| 2024 | 71.07% | -8.12% | 34.60% | -40.23% | 12.42% | -4.42% | -0.73% | 33.09% | -10.04% | -0.20% | -10.67% | -19.63% | 15.70% |
| 2023 | 69.81% | 91.59% | -53.84% | -24.99% | -8.54% | -19.74% | 7.49% | -16.61% | -17.71% | -18.16% | -11.76% | 9.01% | -51.99% |
| 2022 | -8.90% | -7.33% | -4.33% | 1.97% | -27.22% | -69.50% | 0.67% | -6.71% | -25.94% | 6.28% | -9.42% | -18.16% | -89.98% |
| 2021 | -19.74% | -0.98% | -1.41% | -6.86% | -4.40% | 2.24% | 3.04% | -1.27% | -7.35% | -12.43% | -11.15% | -10.27% | -53.06% |
Benchmark Metrics
Addex Therapeutics Ltd has an annualized alpha of 2.98%, beta of 0.40, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since January 29, 2020.
- This stock participated in 208.57% of S&P 500 Index downside but only 19.46% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.40 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 2.98%
- Beta
- 0.40
- R²
- 0.00
- Upside Capture
- 19.46%
- Downside Capture
- 208.57%
Return for Risk
Risk / Return Rank
ADXN ranks 31 for risk / return — below 31% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Addex Therapeutics Ltd (ADXN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ADXN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.30 | ||
| Sortino ratioReturn per unit of downside risk | -2.59 | ||
| Omega ratioGain probability vs. loss probability | 1.02 | 1.37 | -0.35 |
| Calmar ratioReturn relative to maximum drawdown | -0.48 | 2.78 | -3.26 |
| Martin ratioReturn relative to average drawdown | -0.82 | 12.44 | -13.26 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Addex Therapeutics Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Addex Therapeutics Ltd was 98.94%, occurring on Dec 18, 2023. The portfolio has not yet recovered.
The current Addex Therapeutics Ltd drawdown is 98.65%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -98.94%Dec 2023 | 2y 11mo | — | 5y 5moDec 2020 - now |
COVID crash2020 | -57.31%Mar 2020 | 1mo 22d | 4mo 17d | 6mo 9dJan 2020 - Aug 2020 |
2020 bear market2020 | -53.38%Nov 2020 | 3mo 22d | 24d | 4mo 16dAug 2020 - Dec 2020 |
Drawdown Indicators
| ADXN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.94% | -56.78% | -42.16% |
Max Drawdown (1Y)Largest decline over 1 year | -48.31% | -9.10% | -39.21% |
Max Drawdown (3Y)Largest decline over 3 years | -79.71% | -18.90% | -60.81% |
Max Drawdown (5Y)Largest decline over 5 years | -97.64% | -25.43% | -72.21% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -98.65% | -1.80% | -96.85% |
Average DrawdownAverage peak-to-trough decline | -82.12% | -10.71% | -71.41% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 28.09% | 2.03% | +26.06% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Addex Therapeutics Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Addex Therapeutics Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ADXN relative to other companies in the Biotechnology industry. Currently, ADXN has a P/S ratio of 62.1. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ADXN in comparison with other companies in the Biotechnology industry. Currently, ADXN has a P/B value of 1.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ADXN
Add Addex Therapeutics Ltd to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ADXN